Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

Fineline Cube Aug 10, 2022

China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

Fineline Cube Aug 10, 2022

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study

Fineline Cube Aug 10, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...

Company Drug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

Fineline Cube Aug 10, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...

Company Drug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

Fineline Cube Aug 9, 2022

Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...

Company Deals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China

Fineline Cube Aug 9, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment

Fineline Cube Aug 9, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...

Medical Device

GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval

Fineline Cube Aug 9, 2022

Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...

Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia

Fineline Cube Aug 9, 2022

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...

Company Drug

HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy

Fineline Cube Aug 9, 2022

China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...

Company Deals

Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion

Fineline Cube Aug 9, 2022

Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...

Policy / Regulatory R&D

CDE Issues Q&As on COVID-19 Antiviral Drug Evaluation Criteria

Fineline Cube Aug 9, 2022

The Center for Drug Evaluation (CDE) has published a list of Q&As regarding the non-clinical...

Company Medical Device

NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit

Fineline Cube Aug 9, 2022

The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...

Company Deals R&D

BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery

Fineline Cube Aug 8, 2022

Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...

Company Drug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

Fineline Cube Aug 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...

Company Deals Digital

Hywin Holdings to Acquire Life Infinity for Health Management Expansion

Fineline Cube Aug 8, 2022

China-based wealth management firm Hywin Holdings is set to move into the health management business...

Company Drug

HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint

Fineline Cube Aug 8, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...

Company Deals

Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV

Fineline Cube Aug 8, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...

Company Drug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

Fineline Cube Aug 8, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Drug

Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Fineline Cube Aug 8, 2022

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...

Posts pagination

1 … 658 659 660 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.